Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H26N2O4S.ClH |
| Molecular Weight | 414.947 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)(CC1=CC=CC=C1)NCC(O)C2=CC=C(O)C(NS(C)(=O)=O)=C2
InChI
InChIKey=LVNUBJDWJFOMKH-UHFFFAOYSA-N
InChI=1S/C19H26N2O4S.ClH/c1-19(2,12-14-7-5-4-6-8-14)20-13-18(23)15-9-10-17(22)16(11-15)21-26(3,24)25;/h4-11,18,20-23H,12-13H2,1-3H3;1H
| Molecular Formula | C19H26N2O4S |
| Molecular Weight | 378.486 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4144240Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/39574 | https://www.ncbi.nlm.nih.gov/pubmed/8974046 | https://www.ncbi.nlm.nih.gov/pubmed/16601951 | https://www.ncbi.nlm.nih.gov/pubmed/11325796
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4144240
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/39574 | https://www.ncbi.nlm.nih.gov/pubmed/8974046 | https://www.ncbi.nlm.nih.gov/pubmed/16601951 | https://www.ncbi.nlm.nih.gov/pubmed/11325796
Zinterol (MJ-9184-1) is an beta-adregenrgic agonist demostrated activity toward beta1-3 receptors. Oral zinterol caused a fast-appearing and long-lasting bronchodilator effect in patients with with stable chronic obstructive lung disease, however it seems development of zinterol was discontitued.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8098163 | https://www.ncbi.nlm.nih.gov/pubmed/7862834
Curator's Comment: Zinterol (MJ-9184-1) is CNS active in animals. No human study available.
Originator
Sources: https://www.google.com/patents/US3919424
Curator's Comment: Comer and Roth, 1972 (Mead Johnson & Co)
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11325796 |
|||
Target ID: CHEMBL246 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16601951 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors. | 2010-11-30 |
|
| Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges. | 2010-08 |
|
| The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. | 2010-07 |
|
| Laminin enhances beta(2)-adrenergic receptor stimulation of L-type Ca(2+) current via cytosolic phospholipase A(2) signalling in cat atrial myocytes. | 2009-10-15 |
|
| The beta3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human beta3-adrenoceptor. | 2008-11 |
|
| Energy metabolism and memory processing: role of glucose transport and glycogen in responses to adrenoceptor activation in the chicken. | 2008-06-15 |
|
| Arrhythmogenic effects of beta2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. | 2008-06-06 |
|
| beta2-Adrenergic receptor agonists stimulate L-type calcium current independent of PKA in newborn rabbit ventricular myocytes. | 2007-11 |
|
| Beta2- and beta3-adrenoceptors activate glucose uptake in chick astrocytes by distinct mechanisms: a mechanism for memory enhancement? | 2007-11 |
|
| (-)-Adrenaline elicits positive inotropic, lusitropic, and biochemical effects through beta2 -adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. | 2007-03 |
|
| Endurance exercise training attenuates cardiac beta2-adrenoceptor responsiveness and prevents ventricular fibrillation in animals susceptible to sudden death. | 2006-06 |
|
| Agonist effects of zinterol at the mouse and human beta(3)-adrenoceptor. | 2006-05 |
|
| Multiple signalling pathways involved in beta2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells. | 2006-02 |
|
| Temporal dynamics of inotropic, chronotropic, and metabolic responses during beta1- and beta2-AR stimulation in the isolated, perfused rat heart. | 2005-09 |
|
| The cytosolic phospholipase A2 pathway, a safeguard of beta2-adrenergic cardiac effects in rat. | 2005-05-13 |
|
| Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. | 2004-08-31 |
|
| Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. | 2004-01 |
|
| beta2-Adrenergic signaling in human heart: shift from the cyclic AMP to the arachidonic acid pathway. | 2003-11 |
|
| Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)--but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. | 2003-09-30 |
|
| New insights into beta2-adrenoceptor signaling in the adult rat heart. | 2003-03 |
|
| High spinal anesthesia for cardiac surgery: effects on beta-adrenergic receptor function, stress response, and hemodynamics. | 2003-02 |
|
| Opposite action of beta1- and beta2-adrenergic receptors on Ca(V)1 L-channel current in rat adrenal chromaffin cells. | 2003-01-01 |
|
| Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. | 2002-09-20 |
|
| Characterization of the beta-adrenoceptor subtype involved in mediation of glucose transport in L6 cells. | 2002-09 |
|
| Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation. | 2002-07-12 |
|
| Effects of glucose and 2-deoxyglucose on memory formation in the chick: interaction with beta(3)-adrenoceptor agonists. | 2002 |
|
| Beta(2)-adrenergic receptor agonists increase intracellular free Ca(2+) concentration cycling in ventricular cardiomyocytes through p38 and p42/44 MAPK-mediated cytosolic phospholipase A(2) activation. | 2001-10-26 |
|
| Release of norepinephrine from human ovary: coupling to steroidogenic response. | 2001-07 |
|
| Enhanced cardiac L-type calcium current response to beta2-adrenergic stimulation in heart failure. | 2001-07 |
|
| Murine ventricular L-type Ca(2+) current is enhanced by zinterol via beta(1)-adrenoceptors, and is reduced in TG4 mice overexpressing the human beta(2)-adrenoceptor. | 2001-05 |
|
| beta-Adrenergic receptor stimulation of L-type Ca2+ channels in rabbit portal vein myocytes involves both alphas and betagamma G protein subunits. | 2001-02-15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/39574
In double-blind cross-over study including placebo, 0.25 mg and 0.50 mg zinterol (MJ-9184-1) and involving ten patients with stable chronic obstructive lung disease with reversible airways obstruction, MJ-9184-1 caused a fast-appearing and long-lasting bronchodilator effect. The oral intake of 0.50 mg MJ-9184-1, compared to 0.25 mg, caused a more rapid effect and a more pronounced bronchodilation; 0.50 mg MJ-9184-1 also caused some elevation of the pulse rate. The effect was not seen after 0.25 mg MJ-9184-1.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8974046
Zinterol caused positive inotropic and lusitropic effects in the isolated human right atrial appendage with EC50 values of 3 and 2 nM, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:50:17 GMT 2025
by
admin
on
Mon Mar 31 18:50:17 GMT 2025
|
| Record UNII |
569D41K4F5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Mon Mar 31 18:50:17 GMT 2025 , Edited by admin on Mon Mar 31 18:50:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000055466
Created by
admin on Mon Mar 31 18:50:17 GMT 2025 , Edited by admin on Mon Mar 31 18:50:17 GMT 2025
|
PRIMARY | |||
|
37989
Created by
admin on Mon Mar 31 18:50:17 GMT 2025 , Edited by admin on Mon Mar 31 18:50:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL1243407
Created by
admin on Mon Mar 31 18:50:17 GMT 2025 , Edited by admin on Mon Mar 31 18:50:17 GMT 2025
|
PRIMARY | |||
|
569D41K4F5
Created by
admin on Mon Mar 31 18:50:17 GMT 2025 , Edited by admin on Mon Mar 31 18:50:17 GMT 2025
|
PRIMARY | |||
|
C152959
Created by
admin on Mon Mar 31 18:50:17 GMT 2025 , Edited by admin on Mon Mar 31 18:50:17 GMT 2025
|
PRIMARY | |||
|
38241-28-0
Created by
admin on Mon Mar 31 18:50:17 GMT 2025 , Edited by admin on Mon Mar 31 18:50:17 GMT 2025
|
PRIMARY | |||
|
284704
Created by
admin on Mon Mar 31 18:50:17 GMT 2025 , Edited by admin on Mon Mar 31 18:50:17 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |